Issue Date: October 14, 2013
Teva Targets Big Cuts In Staffing
Teva Pharmaceutical Industries is accelerating a cost-cutting program put in place last December. By the end of 2014, the Israeli company will reduce its workforce by about 10%, or 5,000 employees. Through job cuts, asset sales, and improved manufacturing efficiency, it is targeting $2.0 billion in annual savings by the end of 2017. Known primarily as a generic drug firm, Teva has been building its R&D programs and will put some of the savings into programs for complex generics and specialty medicines. The announcement comes soon after Merck & Co. said it would cut 16,000 jobs, nearly 20% of its workforce.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society